| Feature | Standard Omega 5 (Punicic Acid) | PHGDG Omega 5 | |---------|--------------------------------|---------------| | Form | Free fatty acid or triglyceride | Glycerophospholipid (PG headgroup) | | Stability | Oxidizes within 4 weeks | Stabilized >12 months (via dihydrogen phosphate protection) | | Bioavailability | ~12% (enteric) | ~41% (lymphatic + direct cellular uptake) | | Target | Cytosolic PPARs | Mitochondrial inner membrane + PPARγ |
Critical Innovation: The dihydrogen phosphate group on the glycerol backbone prevents premature hydrolysis by pancreatic lipases, allowing the intact PHGDG molecule to enter enterocytes via CD36-mediated transport, not passive diffusion. Phdgd Omega 5
We are currently witnessing the "mainstreaming" of this nutrient. As the global population seeks alternatives to hormone replacement therapy (HRT) and synthetic metabolic drugs, Phdgd Omega 5 offers a botanical bridge. | Feature | Standard Omega 5 (Punicic Acid)
Recent patents filed in Japan and Europe focus on using Phdgd Omega 5 as a preservation agent for other polyunsaturated oils (it acts as a natural antioxidant for Omega-3s). Furthermore, nanotechnology is being applied to encapsulate punicic acid, increasing its bioavailability by 300%, meaning future supplements will require smaller doses for greater effect. We are currently witnessing the "mainstreaming" of this
Via NLRP3 inflammasome inhibition (IC50 = 1.2 µM), PHGDG Omega 5 reduces IL-1β and IL-18 secretion. Simultaneously, it activates PINK1/Parkin-mediated mitophagy only in cells with depolarized mitochondria (ΔΨm < 80 mV) – a hallmark of senescence.
Result: Aged fibroblasts treated with PHGDG Omega 5 showed a 42% reduction in senescence-associated β-galactosidase within 72 hours, with no change in proliferating cells.